In a significant milestone for neural engineering and restorative ophthalmology, Science Corporation has unveiled compelling long-term data for its PRIMA subretinal implant system. The results, presented at the EURETINA Congress in Vienna, indicate that the device provides durable, life-altering vision improvements for patients suffering from geographic atrophy (GA), a severe and debilitating form of age-related macular degeneration (AMD).
As Science Corporation awaits a pivotal regulatory decision from the US Food and Drug Administration (FDA), these findings offer a robust clinical argument for the adoption of the technology, which is already established in European and British markets.
Main Facts: A Paradigm Shift in Retinal Restoration
The PRIMA system represents a sophisticated synergy between hardware and biology. Unlike traditional treatments that rely on pharmacotherapy to slow disease progression, PRIMA is a surgically implanted device designed to replace the function of lost photoreceptor cells.
The device is implanted subretinally in the area of degeneration. It works in tandem with a pair of specialized glasses equipped with a camera and a projection system. The glasses capture visual information and project it as near-infrared light onto the implant. The implant then converts this light into electrical signals, stimulating the remaining healthy cells in the retina to transmit visual information to the brain.
For the five to eight million people living with geographic atrophy globally, the condition typically results in the loss of central vision, rendering tasks such as reading, recognizing faces, and driving nearly impossible. The PRIMA system aims to restore a level of prosthetic sharpness, allowing patients to regain functional independence.
The PRIMAvera Study: A Chronology of Success
The PRIMAvera study (NCT04676854) served as the foundational clinical trial to evaluate the safety and efficacy of the device. The study design was rigorous, tracking participants over a 36-month period to ensure that the initial gains in vision were not only significant but sustainable.
- Initial Implantation and Recovery: The study began with the surgical implantation of the device, followed by a period of patient rehabilitation to learn how to interpret the prosthetic signals provided by the implant.
- The 12-Month Milestone: At the one-year mark, participants demonstrated an average improvement of 24.5 letters on a standard eye chart. This initial success provided the first definitive proof that the device could successfully bridge the gap between light detection and cortical interpretation.
- The 36-Month Milestone: Data released in October 2026 revealed that the improvements did not plateau. By the three-year mark, patients showed an average gain of 29 letters—the equivalent of nearly six lines on an eye test chart.
- Regulatory Presentation: These findings were formally introduced to the international medical community at the EURETINA Congress (October 1–4, 2026), providing a platform for retina specialists to analyze the long-term safety and durability of the system.
Supporting Data: Durability and Efficacy
The statistical findings from the PRIMAvera trial are particularly noteworthy for their consistency. In clinical ophthalmology, "durability" is often the greatest hurdle for prosthetic devices. The progression from 24.5 letters at 12 months to 29 letters at 36 months suggests that the visual cortex continues to adapt and improve its interpretation of the prosthetic input over time.
Of the 18 patients who were evaluable for efficacy, 14 achieved an improvement of at least 15 letters at the 36-month mark. Critically, this improvement occurred without compromising the patients’ existing natural peripheral vision, which remained stable throughout the study.
Safety Profile
Concerns regarding long-term biocompatibility are common with subretinal implants. However, the PRIMAvera trial reported no new safety signals between the 12-month and 36-month checkpoints. While three adverse events were recorded after the first year, none were directly attributed to the PRIMA implant itself, suggesting a favorable long-term safety profile for the hardware. Most serious adverse events were limited to the immediate post-operative period, which is standard for intraocular surgical procedures.
Implications for the US Market and Beyond
The current regulatory climate in the United States places Science Corporation in a position of high visibility. The FDA is currently conducting a thorough review of the device, weighing the PRIMAvera data against existing standards of care.
The Competitive Landscape
Science Corporation is currently a pioneer in this specific subretinal niche, yet they operate within a broader, evolving market. The FDA has previously authorized other technologies, such as LumiThera’s Valeda Light Delivery System, which uses multi-wavelength LED light to stimulate cellular function rather than replacing photoreceptor function.
While Valeda and PRIMA approach the treatment of GA from different technological angles—one focused on cellular repair and the other on visual restoration—they represent a broader shift in ophthalmic device development. According to industry analysis by GlobalData, the ophthalmic devices market is projected to expand at a compound annual growth rate (CAGR) of 4.7%, reaching a total valuation of nearly $15 billion by 2035.
Clinical Impact
For the clinical community, the implications are profound. If the FDA grants approval, physicians will have access to a tool that addresses the consequence of the disease (vision loss) rather than just the symptoms. This creates a potential "gold standard" for patients whose geographic atrophy has rendered them legally blind or severely visually impaired.
Looking Ahead: The Future of Neural Engineering
The success of the PRIMA implant acts as a bellwether for the field of neural engineering. By successfully translating external light into neural signals, Science Corporation has demonstrated that the human retina can act as a viable interface for prosthetic technology even after years of degenerative damage.
As the company prepares for a potential US launch, the focus will likely shift from clinical trials to "real-world evidence." This includes gathering data on how patients utilize the device in their daily lives, the impact on their quality of life, and the long-term maintenance requirements for the hardware.
Furthermore, the integration of these devices into standard care pathways will require a concerted effort from both insurance providers and healthcare systems to ensure equitable access. With a growing aging population, the prevalence of AMD is expected to rise, making the commercial and clinical success of devices like PRIMA not just a technological triumph, but a public health necessity.
In conclusion, the 36-month data from the PRIMAvera study provides a compelling narrative of success. By demonstrating that vision improvement is not only possible but stable and durable, Science Corporation has significantly bolstered its case for US regulatory approval. For millions of patients worldwide, the promise of reclaiming their independence through neural-restorative technology is now closer to reality than ever before. As the industry watches the FDA’s next move, one thing is certain: the era of prosthetic vision has officially arrived, and it is here to stay.
About the Author
